Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety study of Aponermin for relapsed or refractory multiple myeloma
CTR20261061Phase 4Active
- Sponsor
- Wuhan Hiteck Biological Pharma Co., Ltd.
- Start
- Mar 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of aponermin in multiple myeloma (MM), sponsored by Wuhan Hiteck Biological Pharma Co., Ltd.. Started Mar 2026; status: active.
02
Drugs
aponermin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20261061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261061.